대한방사성의약품학회지 (Journal of Radiopharmaceuticals and Molecular Probes)

  • 제10권1호
  • /
  • Pages.83-96
  • /
  • 2024
  • /
  • 2384-1583(pISSN)
  • /
  • 2508-3848(eISSN)
대한방사성의약품학회 (Korean Society of Radiopharmaceuticals and Molecular Probes)
권호 표지
DOI QR코드

DOI QR Code

Peptide-based Radiopharmaceutical for the Tumor Targeting Diagnosis and Treatment

  • Yu Na Ha (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Kwang Il Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS))
  • 투고 : 2024.06.16
  • 심사 : 2024.06.28
  • 발행 : 2024.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Peptide-based radiopharmaceuticals have brought significant advancements in the diagnosis and treatment of various cancers, serving as a powerful tool in nuclear medicine. These radiopharmaceuticals utilize the high specificity of peptides for certain cell receptors, such as the prostate-specific membrane antigen in prostate cancer and somatostatin receptors in neuroendocrine tumors. This review paper aims to describe the clinical benefits of peptide-based radiopharmaceuticals, emphasizing their high target affinity, improved imaging quality, and therapeutic efficacy. By integrating ongoing research and clinical trial data, the innovative impact of peptide-based radiopharmaceuticals in nuclear medicine is highlighted.

키워드

과제정보

This work was supported by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by MSIT, Republic of Korea (No. 50462-2024).

참고문헌

  1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389-427. 
  2. Langer M, Beck-Sickinger AG. Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem Anticancer Agents 2001;1(1):71-93. 
  3. Van Den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004;22(17):3593-607. 
  4. Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 2006;17(6):638-42. 
  5. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004;24(3):357-97. 
  6. Horton DA, Bourne GT, Smythe ML. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Mol Divers 2002;5(4):289-304. 
  7. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508-18. 
  8. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006;17(12):1733-42. 
  9. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28(9):1421-9. 
  10. Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20(12):3049. 
  11. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10(1):9-22. 
  12. S. B. Dowd and E. R. Tilson. Practical radiation protection and applied radiobiology. W. B. Saunders. Philadelphia. 2nd ed. 1999. p. 352. 
  13. Chen H, Zhao L, Fu K, Lin Q, Wen X, Jacobson O, Sun L, Wu H, Zhang X, Guo Z, Lin Q, Chen X. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics 2019;9(25):7948-60. 
  14. Dougherty PG, Sahni A, Pei D. Understanding Cell Penetration of Cyclic Peptides. Chem Rev 2019;119(17):10241-87. 
  15. Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, Eek A, Sosabowski JK, Breeman WA, Reubi JC, Decristoforo C. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2011;38(8):1426-35. 
  16. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273-82. 
  17. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005;12(4):683-99. 
  18. Bodei L, Paganelli G, Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 2006;47(3):375-7. 
  19. Nicolas G, Giovacchini G, Muller-Brand J, Forrer F. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am 2011;40(1):187-204. 
  20. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005;19(4):595-616. 
  21. Rufini V, Calcagni ML, Baum RP. Baum, Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36(3):228-47. 
  22. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43(5):610-6. 
  23. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31(7):1038-46. 
  24. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124-30. 
  25. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23(12):2754-62. 
  26. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46(6):723-34. 
  27. Werner RA, Hanscheid H, Leal JP, Javadi MS, Higuchi T, Lodge MA, Buck AK, Pomper MG, Lapa C, Rowe SP. Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution. Mol Imaging Biol 2019;21(4):790-8. 
  28. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3(9):1165-80. 
  29. Massiere F, Wiedemann N, Borrego I, Hoehne A, Osterkamp F, Paschke M, Zboralski D, Schumann A, Bredenbeck A, Brichory F, Attinger A. Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX. J Nucl Med 2024;65(5):761-7. 
  30. Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2023;29(9):1651-7. 
  31. Guhne F, Radke S, Winkens T, Kuhnel C, Greiser J, Seifert P, Drescher R, Freesmeyer M. Differences in Distribution and Detection Rate of the [68Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer. Pharmaceuticals (Basel) 2021;15(1):9. 
  32. Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ, Schreckenberger M, Ezziddin S, Rosar F. Detection Efficacy of 68Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience. Cancers (Basel) 2023;15(5):1376. 
  33. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008;60(1):1-42. 
  34. Moreno P, Ramos-Alvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets 2016;20(9):1055-73. 
  35. 35. Korner M, Waser B, Rehmann R, Reubi JC. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate 2014;74(2):217-24. 
  36. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999;155(6):2067-76. 
  37. Mattei J, Achcar RD, Cano CH, Macedo BR, Meurer L, Batlle BS, Groshong SD, Kulczynski JM, Roesler R, Dal Lago L, Brunetto AT, Schwartsmann G. Gastrin-releasing peptide receptor expression in lung cancer. Arch Pathol Lab Med 2014;138(1):98-104. 
  38. Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31(6):803-10. 
  39. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002;8(4):1139-46. 
  40. Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A. Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med 2016;57(4):557-62. 
  41. Tang L, Xu M, Zhang L, Qu L, Liu X. Role of αvβ3 in Prostate Cancer: Metastasis Initiator and Important Therapeutic Target. Onco Targets Ther 2020;13:7411-22. 
  42. Chen H, Niu G, Wu H, Chen X. Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics 2016;6(1):78-92. 
  43. Yang G, Phua SZF, Bindra AK, Zhao Y. Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications. Adv Mater 2019;31(10):e1805730. 
  44. Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 2009;27(11):628-35. 
  45. Molek P, Strukelj B, Bratkovic T. Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 2011;16(1):857-87. 
  46. Tan Y, Tian T, Liu W, Zhu Z, J Yang C. Advance in phage display technology for bioanalysis. Biotechnol J 2016;11(6):732-45. 
  47. Bauer D, Sarrett SM, Lewis JS, Zeglis BM. Click chemistry: a transformative technology in nuclear medicine. Nat Protoc 2023;18:1659-68. 
  48. Zeglis BM, Lewis JS. Click Here for Better Chemistry. N Engl J Med 2022;387(24):2291-3. 
  49. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4(2):145-60. 
  50. Park YS, Lee Y, Jin YM, Kim G, Jung SC, Park YJ, Park KD, Jo I. Sustained release of parathyroid hormone via in situ cross-linking gelatin hydrogels improves the therapeutic potential of tonsil-derived mesenchymal stem cells for hypoparathyroidism. J Tissue Eng Regen Med 2018;12(3):e1747-56. 
  51. Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S, Chen X. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008;49(8):1371-9. 
  52. Ferro-Flores G, Ocampo-Garcia B, Cruz-Nova P, Luna-Gutierrez M, Bravo-Villegas G, Azorin-Vega E, Jimenez-Mancilla N, Michel-Sanchez E, Garcia-Perez O, Lara-Almazan N, Santos-Cuevas C. 99mTc-Labeled Cyclic Peptide Targeting PD-L1 as a Novel Nuclear Imaging Probe. Pharmaceutics 2023;15(12):2662.